Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Extrapyramidal symptoms with ritonavir/indinavir plus risperidone.

Deborah V Kelly1, Lizanne C Béïque, M Ian Bowmer

  • 1School of Pharmacy, Memorial University of Newfoundland, 300 Prince Phillip Drive, St. John's, Newfoundland A1B 3V6, Canada. dkelly@pharm.mun.ca

The Annals of Pharmacotherapy
|April 30, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementation and acceptance of pharmacists' prescribing of human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP).

Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC·2025
Same author

Pharmacists' acceptability of provision of sexually transmitted infection services: a scoping review.

The International journal of pharmacy practice·2025
Same author

How to change workflow to enhance implementation of professional services in community pharmacies: A deprescribing case study.

Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC·2024
Same author

Progress towards World Health Organization HIV Infection 95-95-95 measures in Newfoundland and Labrador, Canada.

PloS one·2024
Same author

Strategies to guide the successful implementation of deprescribing in community practice: Lessons learned from the front line.

Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC·2024
Same author

Target users' acceptance of a pharmacist-led prescribing service for pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV).

Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC·2023

A patient experienced severe extrapyramidal symptoms (EPS) when ritonavir and indinavir were added to risperidone treatment. This case highlights a potential drug interaction, advising caution when combining these medications.

Area of Science:

  • Pharmacology
  • Clinical Toxicology
  • Neuroscience

Background:

  • Risperidone is used for tic disorders.
  • Ritonavir and indinavir are antiretroviral medications.
  • Drug interactions can lead to adverse effects.

Observation:

  • A patient on risperidone developed severe swallowing, speaking, and breathing difficulties, along with tremors.
  • These symptoms emerged after initiating ritonavir and indinavir.
  • Discontinuation of risperidone led to significant symptom improvement.

Findings:

  • The patient's symptoms were consistent with neuroleptic-induced acute dystonia and parkinsonism.
  • A drug interaction between ritonavir/indinavir and risperidone is suspected.
  • Inhibition of CYP2D6 and CYP3A4 by antiretrovirals may have caused risperidone accumulation and toxicity.

Related Experiment Videos

Implications:

  • Caution is advised when prescribing risperidone with ritonavir and indinavir.
  • This interaction may occur with other antiretrovirals inhibiting similar metabolic pathways.
  • Further investigation into antiretroviral-antipsychotic interactions is warranted.